Global Regulatory Intelligence
Log in |  Register

Login to your account

Username *
Password *
Remember Me

Create an account

Registering to our Regulatory Updates easy andis should only
take few minutes. To begin, enter your email enter your email
address below so we can check to see if it is already existing
in our records. Your email address will also be used as your
user name when you log in.

Fields marked with an asterisk (*) are required.
Name *
Username *
Password *
Verify password *
Email *
Verify email *
Captcha *
Reload Captcha
   

EU: EMA’s CHMP Adopts Updated Guideline on Manufacture of Finished Dosage Form

Tuesday, August 15, 2017: The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) adopted an updated guideline on what manufacturing process information should be included in the marketing authorization application (MAA).

The update, drafted in July 2015, comes as there has been an increasing trend toward the outsourcing of manufacturing and more complex supply chains.

Details:

More specifically, the guideline offers clarification on the type and level of information that should be included in the common technical document (CTD) Module 3 of the MAA dossier with respect to the manufacturing process description.

"This description should include information about critical steps and intermediates and provides a link between the pharmaceutical development, the proposed control strategy and process validation," the guideline says. "The guideline also addresses aspects related to outsourcing and new manufacturing practices such as complex manufacturing chains or issues with prolonged holding times and transportation conditions."

 
 
 
 
 
 
More Details
© 2016 MakroCare. All Rights Reserved.
  Privacy policy